MBX — MBX Biosciences, Inc. Common Stock

MBX Biosciences, Inc. Common Stock (MBX) is a biotechnology company listed on NASDAQ. It is led by Peter Kent Hawryluk MBA, based in 11711 North Meridian Street, Carmel, IN, United States, 46032, with about 63 employees. MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Net income was -$64.9M. MBX currently screens at market cap $1.98B.

Use this MBX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the MBX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the MBX SEC filings page. Lician reads the product cache first so this HTML stays unique to MBX Biosciences, Inc. Common Stock even when a live quote feed is slow.